The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin; AZD2171) Inhibits Endothelial Cell Function and Growth of Human Renal Tumor Xenografts

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 3, 2009, Pages 897-903

  Siemann, Dietmar W ^a   Brazelle, W D ^a   Jürgensmeier, Juliane M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antiangiogenic therapy; Caki 1 renal cell carcinoma; Cediranib (Recentin, AZD2171)

Indexed keywords

AMINO ACIDS; BIOACTIVITY; BIOLOGICAL MATERIALS; BLOOD VESSEL PROSTHESES; CELL GROWTH; CELLS; CYTOLOGY; GROWTH (MATERIALS); PEPTIDES; PROBABILITY DENSITY FUNCTION; SELF ASSEMBLY; SIGNALING; TUMORS;

ANGIOGENESIS; ANTI-TUMOR EFFECTS; ANTIANGIOGENIC; ANTIANGIOGENIC THERAPY; CAKI-1 RENAL CELL CARCINOMA; CEDIRANIB (RECENTIN, AZD2171); CELL FUNCTIONS; HUMAN MODELS; IN-VITRO; IN-VIVO; SIGNALING INHIBITORS; THERAPEUTIC POTENTIALS; TUBE FORMATIONS; TUMOR CELLS; TUMOR GROWTHS; TUMOR PERFUSIONS; TUMOR XENOGRAFTS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ENDOTHELIAL CELLS;

CEDIRANIB; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; TISSUE PERFUSION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59849084448     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.031     Document Type: Article

References (34)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
2. Hendrix M.J., Seftor E.A., Hess A.R., et al. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer 3 (2003) 411-421
3. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351 (2004) 250-259
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
5. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
6. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
7. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl. 1 (2004) 2-10
8. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
9. McLaughlin J.K., and Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 27 (2000) 115-123
10. Tsui K.H., Shvarts O., Smith R.B., et al. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163 (2000) 1090-1095
11. Yoshino S., Kato M., and Okada K. Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res 20 (2000) 591-594
12. Jacobsen J., Rasmuson T., Grankvist K., et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163 (2000) 343-347
13. Tomisawa M., Tokunaga T., Oshika Y., et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35 (1999) 133-137
14. Harris A.L. Antiangiogenesis for cancer therapy. Lancet 349 Suppl. 2 (1997) SII13-SII15
15. Kerbel R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21 (2000) 505-515
16. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
17. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
18. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
19. Smith K.A., Hill S.A., Begg A.C., et al. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57 (1988) 247-253
20. Curtis A.C.S. Area and volume measurements by random sampling methods. Med Biol Illustra 10 (1960) 261-266
21. Jain R.K., Duda D.G., Clark J.W., et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40
22. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
23. Elaraj D.M., White D.E., Steinberg S.M., et al. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 27 (2004) 259-264
24. Rini B.I., Halabi S., Taylor J., et al. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10 (2004) 2584-2586
25. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
26. Drevs J., Siegert P., Medinger M., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25 (2007) 3045-3054
27. Hanrahan E.O., and Heymach J.V. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13 Suppl. (2007) S4617-S4622
28. Ryan C.J., Stadler W.M., Roth B., et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25 (2007) 445-451
29. van Herpen C., Drevs J., van Cruijsen H., et al. Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies. [Abstract]. Proc Am Soc Clin Oncol 25 (2007) 3560
30. Sridhar S.S., Hotte S.J., Mackenzie M.J., et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. [Abstract]. Proc Am Soc Clin Oncol 5 (2007) 5093
31. Bozec A., Formento P., Lassalle S., et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 97 (2007) 65-72
32. Smith N.R., James N.H., Oakley I., et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6 (2007) 2198-2208
33. Williams K.J., Telfer B.A., Shannon A.M., et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 6 (2007) 599-606
34. Horsman M.R., and Siemann D.W. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 66 (2006) 11520-11539